Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
· Electromedical & Electrotherapeutic Apparatus
RESEARCH SNAPSHOTCapsoVision, Inc's latest supported as-filed period reports revenue of $3.6M; gross margin moved 327 basis points lower on the same comparison basis. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.00% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -230.66% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 9.89% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 129.12% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 51.36% · CORE
Level · gp.fundamentals.operating_margin
Raw value -208.07% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Gross margin changed -327 basis points from the comparable as-filed period.
Gross profit changed +3.3% from the comparable as-filed period.
Inventory changed +54.6% from the comparable as-filed period.
Net income changed -61.8% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
CV · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001378325-26-000039SEC ↗10-QAug 13, 2026Period Jun 30, 20260001378325-26-000036SEC ↗8-KAug 13, 2026Period Aug 13, 20260001378325-26-000035SEC ↗4Jul 21, 2026Period Jul 17, 20260001009165-26-000006SEC ↗4Jul 10, 2026Period Jul 8, 20260001009165-26-000005SEC ↗4Jul 7, 2026Period Jun 26, 20260001009165-26-000004SEC ↗4Jul 2, 2026Period Jul 1, 20260002140339-26-000004SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 17, 2026Filed Jul 21, 2026 | HARARI ELIYAHOU ET ALReporting owner | Open Market PurchaseIndirect | 61,068 | $7 | $410,988 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 145.73% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 15.45% · OPTIONAL
Operating income changed -63.0% from the comparable as-filed period.
Operating margin changed -6777 basis points from the comparable as-filed period.
Research & development changed +56.5% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001378325-26-000026